Biocryst Pharmaceuticals (BCRX) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 36.43% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -532.04% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -60.78% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 176.09% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1,170.12% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 228.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 228.60% |
| Mar 31, 2026 | -4,026.02% |
| Dec 31, 2025 | 10,090.73% |
| Sep 30, 2025 | 385.80% |
| Jun 30, 2025 | 289.62% |
| Mar 31, 2025 | 252.83% |
| Dec 31, 2024 | 89.38% |
| Sep 30, 2024 | 171.07% |
| Jun 30, 2024 | 149.47% |
| Mar 31, 2024 | 43.00% |
| Dec 31, 2023 | 0.83% |
| Sep 30, 2023 | 38.09% |
| Jun 30, 2023 | 50.46% |
| Mar 31, 2023 | 50.51% |
| Dec 31, 2022 | 37.00% |
| Sep 30, 2022 | 77.71% |
| Jun 30, 2022 | 34.06% |
| Mar 31, 2022 | 47.36% |
| Dec 31, 2021 | 70.26% |
| Sep 30, 2021 | 78.43% |